Suven Life Sciences granted patents in Canada and China
Biopharma firm Suven Life Sciences has reportedly been granted patents for a drug used in the treatment of neurodegenerative diseases.
As confirmed by PTI, the company has now been granted two patents from Canada and one patent in China foe drug used for treatments for diseases which include Alzheimer's, Schizophrenia and Parkinson's. The patents will be valid through 2029 and 2030, as confirmed by the company.
With this development, Suven Life Sciences' total count of patents stands at 20 from Canada and 18 from China.
Suven Life Sciences CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for major depressive disorders (MDD) with high unmet medical need with huge market potential globally."
In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases."
As confirmed by PTI, the company has now been granted two patents from Canada and one patent in China foe drug used for treatments for diseases which include Alzheimer's, Schizophrenia and Parkinson's. The patents will be valid through 2029 and 2030, as confirmed by the company.
With this development, Suven Life Sciences' total count of patents stands at 20 from Canada and 18 from China.
Suven Life Sciences CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for major depressive disorders (MDD) with high unmet medical need with huge market potential globally."
In a BSE filing, the company said it has been granted "two product patents from Canada and one product patent from China corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.